肾癌伴静脉瘤栓根治性肾切除术后转移的简化预测工具
本研究纳入2000至2021年532例接受肾切除加静脉瘤栓取出术的M0肾细胞癌患者,利用LASSO回归筛选变量并构建列线图,内部及两家外部队列验证5年无转移生存预测。列线图含瘤栓水平、肿瘤坏死、肉瘤样特征和pN分期,5年AUC内部均为0.74,外部为0.71和0.68。决策曲线分析显示在阈值概率0.33至0.80区间列线图增加净获益。
要点
- 列线图基于瘤栓水平、肿瘤坏死、肉瘤样特征和pN分期预测5年无转移生存。
- 内部验证5年AUC为0.74,两个外部队列分别为0.71和0.68。
- 决策曲线分析示阈值概率0.33至0.80时列线图增加净获益,可辅助辅助治疗选择。
核心结论
- 提供了一个经内部和外部验证的5年无转移生存风险计算器,用于肾切除加瘤栓取出术后患者。
- 该预后工具可能用于指导辅助治疗选择和协助临床试验设计。
研究设计与样本
- 评估2000至2021年532例接受肾切除加静脉瘤栓取出术的M0肾细胞癌患者。
- 采用70-30拆分(训练集和测试集)及LASSO回归筛选与复发独立相关的变量。
- 构建列线图并在两个独立机构数据集进行内部和外部验证。
- 针对辅助帕博利珠单抗使用进行决策曲线分析。
主要发现
- 瘤栓水平0至4级患者分别为278例(52.3%)、66例(12.4%)、116例(21.8%)、35例(6.6%)和37例(7.0%)。
- 总体估计5年无转移生存率为41.3%。
- 列线图由瘤栓水平、肿瘤坏死、肉瘤样特征和pN分期组成。
- 5年AUC在内部测试集和训练集均为0.74,在两个外部队列分别为0.71和0.68。
- 决策曲线分析显示列线图在阈值概率0.33至0.80之间增加净获益。
关键数值与推荐
- 列线图预测5年无转移生存,包含瘤栓水平、肿瘤坏死、肉瘤样特征和pN分期。
- 内部验证5年AUC为0.74,外部验证5年AUC为0.71和0.68。
- 决策曲线分析中列线图在阈值概率0.33至0.80区间增加净获益。
临床怎么用
- 可用于肾切除加瘤栓取出术后M0肾细胞癌患者的5年无转移生存风险评估。
- 可能辅助筛选适合辅助治疗的患者并协助临床试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and comprehensively validate a simplified and easy-to-use prediction tool for the risk of metastatic recurrence after surgery for non-metastatic renal cell carcinoma with an associated venous tumor thrombus. SUBJECTS/PATIENTS AND METHODS: We evaluated 532 patients who underwent nephrectomy and venous thrombectomy for M0 RCC from 2000 to 2021. Clinicopathological and surgical data were analyzed. A 70-30 split (test and train cohort, respectively) and the least absolute shrinkage and selection operation regression (LASSO) model were used to select variables independently associated with recurrence. We developed a nomogram and validated it both internally and externally with 2 separate institutional datasets. Additionally, we performed decision curve analysis for the use of adjuvant Pembrolizumab. RESULTS: We included 278 (52.3%), 66 (12.4%), 116 (21.8%), 35 (6.6%), and 37 (7.0%) patients with level zero through 4 tumor thrombi, respectively. Overall, estimated 5-year metastasis-free survival (MFS) was 41.3%. The resulting nomogram was composed of thrombus level, tumor necrosis, sarcomatoid features, and pN stage. AUC at 5 years was 0.74 in both our internal test and train cohorts, and 0.71 and 0.68 in 2 external cohorts. On decision curve analytics, our nomogram adds net benefit at a threshold probability between 0.33 and 0.80. CONCLUSION: We provide an internally and externally validated risk calculator for 5-year MFS following radical nephrectomy with tumor thrombectomy. This prognostic tool may be used to guide selection for adjuvant therapies and to assist in clinical trial design.
引用
- Roberson DS, Basourakos SP, Cheville JC, et al. A Simplified Prediction Tool for Metastasis After Nephrectomy With Venous Tumor Thrombectomy for RCC. Urology. 2026. PMID: 41643777. doi:10.1016/j.urology.2026.01.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。